abemaciclib
Sign in to saveAbemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
Key facts
- Drug.image
- Abemaciclib.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Verzenio, Verzenios, Ramiven, others
- Drug.DailyMedID
- Abemaciclib
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EF03
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 45%
- Drug.protein_bound
- 96.3%
- Drug.elimination_half life
- 18.3 hrs
- Drug.excretion
- 81% via feces, 3% via urine
- Drug.CAS_number
- 1231929-97-7
- Drug.PubChem
- 46220502
via Wikipedia infobox
Article
9 sectionsContents
- Medical uses
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Clinical trials
- Chemistry
- References
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
It was designated as a breakthrough therapy for breast cancer by the US Food and Drug Administration (FDA) in October 2015.